0000950170-24-073238.txt : 20240613 0000950170-24-073238.hdr.sgml : 20240613 20240613191850 ACCESSION NUMBER: 0000950170-24-073238 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20240605 FILED AS OF DATE: 20240613 DATE AS OF CHANGE: 20240613 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: CAIN CHRISTOPHER W. CENTRAL INDEX KEY: 0001817733 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38443 FILM NUMBER: 241042661 MAIL ADDRESS: STREET 1: 2001 MARKET STREET STREET 2: SUITE 2500 CITY: PHILADELPHIA STATE: PA ZIP: 19103 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cogent Biosciences, Inc. CENTRAL INDEX KEY: 0001622229 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 465308248 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 275 WYMAN STREET STREET 2: 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 BUSINESS PHONE: 617-945-5576 MAIL ADDRESS: STREET 1: 275 WYMAN STREET STREET 2: 3RD FLOOR CITY: WALTHAM STATE: MA ZIP: 02451 FORMER COMPANY: FORMER CONFORMED NAME: Unum Therapeutics Inc. DATE OF NAME CHANGE: 20180402 FORMER COMPANY: FORMER CONFORMED NAME: Unum Therapeutics, Inc. DATE OF NAME CHANGE: 20141014 4 1 ownership.xml 4 X0508 4 2024-06-05 0001622229 Cogent Biosciences, Inc. COGT 0001817733 CAIN CHRISTOPHER W. C/O COGENT BIOSCIENCES, INC. 275 WYMAN STREET, 3RD FLOOR WALTHAM MA 02451 true false false false false Stock Option (Right to Buy) 8.92 2024-06-05 4 A false 44700 0.00 A 2034-06-05 Common Stock 44700 44700 D This stock option shall vest in full upon the earlier of the first anniversary of the date of grant or the date of the 2025 Annual Meeting of Stockholders. Under the Reporting Person's arrangement with Fairmount Funds Management LLC (the "Adviser"), the Reporting Person holds the option for one or more investment vehicles managed by the Adviser (each, a "Fairmount Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received from the option for the benefit of such Fairmount Fund. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. /s/ Evan D. Kearns, Attorney-in-Fact 2024-06-13